Outlook Therapeutics, Inc.（纳斯达克代码：OTLK）近日披露了与美国食品药品监督管理局（FDA）就眼科药物ONS-5010/Lytenava™（贝伐珠单抗-Vikg）举行A类会议后的关键动态。此次会议聚焦于该药物用于治疗湿性年龄相关性黄斑变性（wet-AMD）的监管路径，双方就后续申报策略达成重要共识。
公司表示，与FDA的深入交流进一步明确了生物制品许可申请（BLA）所需补充的数据要求及临床开发计划。此次沟通为ONS-5010/Lytenava™的审评进程提供了更清晰的指引，有望加速其商业化进程。若获批，该药物将成为美国首个用于眼科给药的贝伐珠单抗制剂，填补湿性AMD治疗领域的市场空白。
Outlook Therapeutics强调将继续与FDA保持密切协作，积极推进药物上市准备工作。市场分析指出，此次会议进展消除了部分监管不确定性，为产品未来市场表现注入积极信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.